EGFR and non-small cell lung carcinoma: Notably, 10 patients (24.4%) were heavily pretreated, with at least 3 lines of prior treatment, and 11 (26.8%) had gene alterations that are correlated with poor response to ICI treatment, such as activated EGFR variants,5,29,30,31,32ALK amplification,30JAK loss,33 and DNMT3A variants.34 Only approximately 20% of the enrolled patients exhibited positive PD-L1 expression, lower than the reported prevalence of PD-L1 expression in NSCLC.35 These indices might partially explain why our study presented inferior ORR.